Walleye Trading’s Japer Therapeutics Warrants JSPRW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-34,142
Closed -$2.72K 4605
2025
Q3
$2.72K Hold
34,142
﹤0.01% 4268
2025
Q2
$4.26K Hold
34,142
﹤0.01% 4104
2025
Q1
$4.88K Sell
34,142
-996
-3% -$157 ﹤0.01% 3890
2024
Q4
$7.38K Buy
35,138
+21,043
+149% +$4.42K ﹤0.01% 4056
2024
Q3
$2.82K Hold
14,095
﹤0.01% 3895
2024
Q2
$2.82K Hold
14,095
﹤0.01% 4022
2024
Q1
$2.56K Hold
14,095
﹤0.01% 4497
2023
Q4
$1.13K Hold
14,095
﹤0.01% 4899
2023
Q3
$705 Hold
14,095
﹤0.01% 4898
2023
Q2
$1.98K Hold
14,095
﹤0.01% 4500
2023
Q1
$2.82K Hold
14,095
﹤0.01% 4588
2022
Q4
$423 Hold
14,095
﹤0.01% 4864
2022
Q3
$1K Hold
14,095
﹤0.01% 4878
2022
Q2
$1K Hold
14,095
﹤0.01% 4999
2022
Q1
$4K Hold
14,095
﹤0.01% 5139
2021
Q4
$21K Sell
14,095
-26,758
-65% -$37.3K ﹤0.01% 4916
2021
Q3
$60K Buy
+40,853
New +$43.7K ﹤0.01% 4587
2021
Q1
Sell
-20,790
Closed -$30K 5038
2020
Q4
$30K Sell
20,790
-9,210
-31% -$11.5K ﹤0.01% 4313
2020
Q3
$34K Buy
+30,000
New +$30.3K ﹤0.01% 3736

Other funds holding JSPRW

Walleye Trading's JSPRW Position: Q4 2025 in Review

Walleye Trading sold out of Japer Therapeutics Warrants (JSPRW) in Q4 2025, closing a stake of 34,142 shares — an estimated $2.72K sold.

Walleye Trading first reported a position in JSPRW in Q3 2020 and held it in 19 quarters. The position peaked at $60K in Q3 2021. 9 funds tracked by Wall St. Rank hold JSPRW as of Q4 2025.

  • Walleye Trading reported no remaining Japer Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
  • Walleye Trading sold 34,142 Japer Therapeutics Warrants shares in Q4 2025, an estimated $2.72K.
  • Walleye Trading first reported a position in Japer Therapeutics Warrants in Q3 2020 and held it in 19 quarters.
  • Walleye Trading's Japer Therapeutics Warrants position peaked at $60K in Q3 2021.
  • 9 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q4 2025.

Based on Walleye Trading's 13F filing for Q4 2025, filed 13 Feb 2026.